Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

Lisa M. Neff; Michelle Weil; Alan Cole; Thomas R. Hedges; William Shucart; Donald Lawrence; Jay Jiguang Zhu; Arthur S. Tischler; Ronald M. Lechan

doi:10.1007/s11102-007-0014-1

Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

Lisa M. Neff, Michelle Weil, Alan Cole, Thomas R. Hedges, William Shucart, Donald Lawrence, Jay Jiguang Zhu, Arthur S. Tischler, Ronald M. Lechan^*

^*Corresponding author for this work

Medicine, Endocrinology Division

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Abstract

Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.

Original language	English (US)
Pages (from-to)	81-86
Number of pages	6
Journal	Pituitary
Volume	10
Issue number	1
DOIs	https://doi.org/10.1007/s11102-007-0014-1
State	Published - Mar 2007

Keywords

Dopamine agonist resistance
Prolactinoma
Temozolomide

ASJC Scopus subject areas

Endocrinology
Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11102-007-0014-1

Cite this

@article{57b29a089e78490dbbfd21533b3cc7f5,

title = "Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists",

abstract = "Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.",

keywords = "Dopamine agonist resistance, Prolactinoma, Temozolomide",

author = "Neff, {Lisa M.} and Michelle Weil and Alan Cole and Hedges, {Thomas R.} and William Shucart and Donald Lawrence and Zhu, {Jay Jiguang} and Tischler, {Arthur S.} and Lechan, {Ronald M.}",

year = "2007",

month = mar,

doi = "10.1007/s11102-007-0014-1",

language = "English (US)",

volume = "10",

pages = "81--86",

journal = "Pituitary",

issn = "1386-341X",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

AU - Neff, Lisa M.

AU - Weil, Michelle

AU - Cole, Alan

AU - Hedges, Thomas R.

AU - Shucart, William

AU - Lawrence, Donald

AU - Zhu, Jay Jiguang

AU - Tischler, Arthur S.

AU - Lechan, Ronald M.

PY - 2007/3

Y1 - 2007/3

N2 - Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.

AB - Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.

KW - Dopamine agonist resistance

KW - Prolactinoma

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=34147157741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147157741&partnerID=8YFLogxK

U2 - 10.1007/s11102-007-0014-1

DO - 10.1007/s11102-007-0014-1

M3 - Article

C2 - 17285366

AN - SCOPUS:34147157741

SN - 1386-341X

VL - 10

SP - 81

EP - 86

JO - Pituitary

JF - Pituitary

IS - 1

ER -

Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this